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A disequilibrium between pro-and anti-angiogenic stimuli, due to various insults including ischemia, infection, inflammation and trauma causes corneal neovascularization (CoNV) [1] . Several established therapies such as steroids, nonsteroidal anti-inflammatory drugs, cyclosporin A, corneal limbal cell transplantation, and argon laser photocoagulation are available to treat CoNV. However, there remains no clear consensus on the best treatment [2] . Heparin has been used as an anti-coagulant for several decades. Recent studies have shown that it has anti-angiogenic effects in addition to anti-inflammatory and immunomodulating effects [3] . Chemically modified heparin derivatives have also been reported to show advanced anti-angiogenic activity with decreased anti-coagulation effects and less complications due to bleeding [4] [5] . A modified heparin derivative, 7-taurocholic acid conjugated low-molecular weight heparin (LHT7) has been proven to be a potent anti-angiogenic effects [6] . Several previous studies have also demonstrated that low-molecular weight heparin (LMWH) inhibits CoNV in experimental animal models [7] [8] [9] [10] . However, the route of administration and dosage of heparin in the treatment of CoNV have varied from study to study. In addition the ocular pharmacokinetics and biodistribution of administered heparin is not well documented.
A recently introduced in vivo optical imaging system has provided valuable information on the biodistribution, stability, and clearance profiles of a variety of pharmaceutical agent in a non-invasive manner. Notably, the in vivo fate of near-infrared (NIR) fluorescent-probe-labeled substances can be easily monitored using this system [11] [12] . In our current study, we assessed the ocular biodistribution and clearance of topically administered LHT7 using an in vivo optical imaging system in a mouse model of neovascularized cornea. 
MAtERIALS And MEthodS

Corneal neovascularization Mouse Model
For intra-animal comparisons, CoNV was only induced in the inferior cornea (IC). These procedures were performed under anesthesia via an intraperitoneal injection of zolazepam (80 mg/kg) and xylazine hydrochloride (10 mg/kg). Proparacaine hydrochloride at a 0.5% concentration (Alcaine; Alcon-Couvreur, Puurs, Belgium) was also topically applied. For suture-induced CoNV, marks were created in the IC at 1 mm from the limbus. Two interrupted sutures were placed through the epithelium and stroma with 10-0 nylon (AA-2626; Sharpoint, Surgical Specialties Corp., Vancouver, Canada). These sutures did not penetrate the endothelial layer. The corneal surface was then rinsed with 10 mL balanced salt solution (Alcon Laboratories, Fort Worth, TX, USA).
The development of CoNV was evaluated for one week after the suturing procedure. Annular sectorial areas of the CoNV ( Figure 1 ) were then measured as follows where Ɵ is the central angle (radians), r 1 is the radius of the corneal center to CoNV starting point and r 2 is the radius of the corneal center to CoNV end point. taurocholic Acid-conjugated Low-molecular Weight heparin LHT7 was synthesized according to a previously described method [13] . Briefly, a primary amine was introduced into 4-hydroxyl sodium taurocholate and cholic acid by activating the hydroxyl group using 4 nitrophenyl chloroformate (Sigma-Aldrich, St. Louis, MO, USA) in the presence of triethylamine (Sigma-Aldrich), followed by the addition of excessive ethylenediamine (Sigma-Aldrich). The carboxylic group of the cholic acid was protected in advance. Ethylenediamine-introduced sodium taurocholate was conjugated onto LMWH (Fraxiparin; Glaxo Smith Kline, Genval, Belgium) via its carboxylate groups through the 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDAC)/ N-hydroxysuccinimide (NHS) coupling method to produce LHT7. The NIR fluorescence cyanine (Cy) dye, Cy5.5, was used as the fluorescent probe due to its ability to penetrate tissues, its small size, good aqueous solubility, pH insensitivity in the 3-10 range, and low non-specific binding [14] . Cy5.5 NHS ester was purchased from the Lumiprobe Corporation (Hallandale Beach, FL, USA) and used to synthesize Cy5.5 labeled LHT7. LHT7 was weighed and dissolved in sterile water by ultrasonic agitation prior to use. In vivo optical Imaging An in vivo optical imaging system (Optix MX3 Molecular Imaging System, Advanced Research Technology, Inc., Montreal, Canada) was used to determine were not significant. The SC intensity of LHT7-Cy5.5 was significantly lower at 6h than at 5min (P=0.042; Figure 2 ). In recent years, biodistribution analyses of pharmaceutical compounds in preclinical animal models have become an integral part of drug development [15] . In our previous study, we reported that LHT7 efficiently inhibits CoNV in an experimental animal model [8] . In our present study, we investigated the ocular biodistribution of topically applied LHT7 using in vivo optical imaging in a mouse model of CoNV. Traditionally, to evaluate the tissue distribution of a biochemical substance, tissue histology has been necessary. Subsets of animals would thus be sacrificed at different time points to determine the temporal patterns of distributions and levels of the substance. This approach is therefore costly and lengthy; furthermore, it requires a large number of animals. It also decreases the statistical power of the experiment because each animal is only measured once and cannot be its own control [16] . In vivo optical imaging has offered an opportunity to measure the biodistribution of a pharmaceutical at multiple time points, non-destructively, and reduce the variance associated with inter-animal comparisons. It also makes it possible to observe the physiology of an animal in real-time rather than relying on a static post-mortem histology. Many experimental and clinical applications of optical imaging have been explored [17] [18] .
Biodistribution of
Moreover, this field have continued to evolve. Novel types of luminescent probes including nanocluster material have been introduced, which are have high fluorescence, good photostability, non-toxicity and excellent biocompatibility [19] . Deep optical imaging of tissue has been reported using the second and third NIR spectral windows to reduce scattering, minimize absorption then enhance image quality [20] . However, to the best of our knowledge, our current study is the first to use in vivo optical imaging for ocular biodistributional assessment. In vivo optical imaging must address a trade-off between the depth of targeted tissues and the resolution of the image produced. The eyes are exposed organ, therefore they have properties suitable for in vivo optical imaging. In this study, we utilized the relatively simple fluorescent probe, Cy5.5, and did not applicate additional steps otherwise conventional in vivo optical imaging process. Nevertheless, acquired images were discernible and measurable and we found that it is usable for biodistribution evaluations of a pharmaceutical agent. To verify the usefulness of in vivo optical imaging for ocular biodistribution in various material and optimize the image quality, further studies will be needed.
Topically-administered LHT7 showed a high abundance at the CoNV areas of the subject mice for 4h but this level dropped by more than 50% at 6h after instillation. In contrast, LHT7 demonstrated a low distribution in normal corneas, and free cyanine also produced comparably low signals in both neovascularized and normal mouse corneas, without a difference. Vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) play significant roles in neovascularization including CoNV, and platelet-derived growth factor B (PDGF-B) is a key factor in stabilizing the primitive vascular network by recruiting mural cells to the endothelium [21] [22] . LHT7 has been found to inhibit multiple stages of angiogenesis by blocking VEGF, FGF2, and PDGF-B [6] . Undoubtedly, definite clinical effect of LHT7 on
CoNV regression have to be determined using gross manner.
In our other experimental study, we evidenced that topical administration of LHT7 has an effect on CoNV regression and prevention [9] . The high distribution of LHT in CoNV areas reinforce the assumption that LHT7 interacts with the angiogenic factors. With regard to the half-life, our present results suggest that topically administered LHT7 maintains its effects for at least 4h, and that additional application would therefore be needed every 4 to 6h.
There were a number of limitations to the present study. We did not establish a therapeutic window, and did not evaluate the relationship between the biodistribution level and pharmacological effects of LHT7. Further investigations will be needed to determine the correlation between the clinical effectiveness and biodistributional degree. In conclusion, topically-administered LHT7 shows a high biodistribution in CoNV areas in the mouse for 4h after its topical application at the cornea. Additional applications would thus be required every 4 to 6h to maintain its distribution level.
In vivo optical imaging with an NIR probe is a useful approach to evaluating the ocular biodistribution of pharmacological agents in an animal model. 
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